Clinical trial · Observational
Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Despite the common application of radiotherapy in cancer treatment, the prediction of radiosensitivity and treatment response has not yet entered the era of precision medicine. Therefore, development of genome-based methods for predicting radiosensitivity and treatment response is a central goal of radiation oncology. In the previous study, the investigators have identified a set of novel potential biomarkers associated with radiosensitivity and recurrence，through correlating patients' genomic profiles with toxicity, disease progression and overall survival after RT.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Radiation Toxicity | — | UNRESOLVED | — |
| Radiosensitivity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| next generation sequence | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- non-smell cell lung cancer (NSCLC)
- description
- Advanced NSCLC patients receiving radiotherapy or chemo-radiotherapy
- interventionNames
- Genetic: next generation sequence
- label
- Rectal cancer
- description
- Rectal cancer patients receiving neoadjuvant radiotherapy or chemo-radiotherapy
- interventionNames
- Genetic: next generation sequence
- label
- Smell cell lung cancer (SCLC)
- description
- SCLC patients receiving radiotherapy or chemo-radiotherapy
- interventionNames
- Genetic: next generation sequence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with locally advanced solid tumors (lung cancer, esophageal cancer, rectal cancer (neoadjuvant), cervical cancer, nasopharyngeal carcinoma cancer and liver cancer) identified by cytology and pathology; 2. Patients need conventional fractionation and adequate radiotherapy; 3. Age ≥ 18 years old, male and female; 4. Expected survival time ≥ 12 weeks; 5. PS score 0-2 within 2 weeks before admission to the group; 6. There are tumor tissue samples and blood samples can be used for NGS inspection; 7. Patients volunteered to join this study, sign informed consent, provide all diagnosis and treatment data after cancer diagnosis before entering the group, good compliance, cooperate with follow-up. Exclusion Criteria: 1. The patient's previous radiation therapy leads to overlapping potential fields; 2. Stage IV patients and stage I patients to be treated with SBRT 3. The patient cannot receive regular imaging examinations; 4. Any serious or uncontrolled signs of systemic disease that the investigator believes may significantly affect the patient's risk/benefit balance, including hepatitis B, hepatitis C, and human immunodeficiency virus; 5. The researcher believes that it is not suitable for the group.
References
Publications (0)
Data not yet available